Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Audrey van Drogen

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Nature Cancer|April 20, 2023
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaKlara Kropivsek, Paul Kachel, Sandra Goetze, et al.
Nature Communications|February 17, 2019
ASPP proteins discriminate between PP1 catalytic subunits through their SH3 domain and the PP1 C-tailM Teresa Bertran, Stéphane Mouilleron, Yanxiang Zhou, et al.
Nature Biotechnology|February 20, 2019
Multi-omic measurements of heterogeneity in HeLa cells across laboratoriesYansheng Liu, Yang Mi, Torsten Mueller, et al.
Nature Communications|October 12, 2023
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosisMattheus H E Wildschut, Julien Mena, Cyril Dördelmann, et al.
Nature Medicine|September 20, 2024
High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activitySohyon Lee, Tobias Weiss, Marcel Bühler, et al.
Nature Metabolism|January 30, 2023
Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiencyPatrick Forny, Ximena Bonilla, David Lamparter, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Nature Cancer|April 20, 2023
Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myelomaKlara Kropivsek, Paul Kachel, Sandra Goetze, et al.
Nature Communications|February 17, 2019
ASPP proteins discriminate between PP1 catalytic subunits through their SH3 domain and the PP1 C-tailM Teresa Bertran, Stéphane Mouilleron, Yanxiang Zhou, et al.
Nature Biotechnology|February 20, 2019
Multi-omic measurements of heterogeneity in HeLa cells across laboratoriesYansheng Liu, Yang Mi, Torsten Mueller, et al.
Nature Communications|October 12, 2023
Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosisMattheus H E Wildschut, Julien Mena, Cyril Dördelmann, et al.
Nature Medicine|September 20, 2024
High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activitySohyon Lee, Tobias Weiss, Marcel Bühler, et al.
Nature Metabolism|January 30, 2023
Integrated multi-omics reveals anaplerotic rewiring in methylmalonyl-CoA mutase deficiencyPatrick Forny, Ximena Bonilla, David Lamparter, et al.
Pageof 2